Literature DB >> 10480735

Neuraminidase inhibitors as anti-influenza virus agents.

C U Kim1, X Chen, D B Mendel.   

Abstract

Influenza virus neuraminidase (NA) catalyses the cleavage of sialic acid residues terminally linked to glycoproteins and glycolipids and plays an important role in the replication of the virus. Recently, several potent NA inhibitors have been synthesized based on the rational design of mimicking the transition state of the sialic acid cleavage. Zanamivir and oseltamivir (GS 4104, the prodrug of GS 4071) have emerged as promising influenza NA inhibitors for the treatment and prophylaxis of human influenza virus infection. This review describes the recent work toward the discovery and development of influenza NA inhibitors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10480735     DOI: 10.1177/095632029901000401

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  24 in total

1.  Analysis of inhibitor binding in influenza virus neuraminidase.

Authors:  B J Smith; P M Colman; M Von Itzstein; B Danylec; J N Varghese
Journal:  Protein Sci       Date:  2001-04       Impact factor: 6.725

2.  Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries.

Authors:  Matthias Hochgürtel; Heiko Kroth; Dorothea Piecha; Michael W Hofmann; Claude Nicolau; Sonja Krause; Otmar Schaaf; Gabriele Sonnenmoser; Alexey V Eliseev
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

Review 3.  The significance of G protein-coupled receptor crystallography for drug discovery.

Authors:  John A Salon; David T Lodowski; Krzysztof Palczewski
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

4.  Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers.

Authors:  Ganesh R Iyer; Sam Liao; Joseph Massarella
Journal:  AAPS PharmSci       Date:  2002

5.  Structure-aided drug development of potential neuraminidase inhibitors against pandemic H1N1 exploring alternate binding mechanism.

Authors:  Khushboo D Malbari; Anand S Chintakrindi; Lata R Ganji; Devanshi J Gohil; Sweta T Kothari; Mamata V Joshi; Meena A Kanyalkar
Journal:  Mol Divers       Date:  2019-02-01       Impact factor: 2.943

6.  Source of oseltamivir resistance due to single E119D and double E119D/H274Y mutations in pdm09H1N1 influenza neuraminidase.

Authors:  Chonnikan Hanpaibool; Matina Leelawiwat; Kaito Takahashi; Thanyada Rungrotmongkol
Journal:  J Comput Aided Mol Des       Date:  2019-11-26       Impact factor: 3.686

7.  Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.

Authors:  Michael Z Wang; Chun Y Tai; Dirk B Mendel
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

8.  Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.

Authors:  Ha T Nguyen; Tiffany G Sheu; Vasiliy P Mishin; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

9.  In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.

Authors:  Akhteruzzaman Molla; Warren Kati; Robert Carrick; Kevin Steffy; Yan Shi; Debra Montgomery; Nanette Gusick; Vincent S Stoll; Kent D Stewart; Teresa I Ng; Clarence Maring; Dale J Kempf; William Kohlbrenner
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

10.  Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors.

Authors:  Vasiliy P Mishin; Dmitri Novikov; Frederick G Hayden; Larisa V Gubareva
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.